PF-Atlas › Clinical Trials › NCT02709109
A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
VX-371 + HS · Phase 2
Registry ID
NCT02709109
Phase
Phase 2
Status
Completed
Drug / intervention
VX-371 + HS
Sponsor
Parion Sciences
Start
2016-02
Enrollment
147
Locations
40
About this trial
The purpose of this study is to evaluate the safety and efficacy of treatment with VX-371 in hypertonic saline compared to hypertonic saline alone in subjects with cystic fibrosis (CF) who are ≥12 years of age, homozygous for the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutation, and being treated with Orkambi
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02709109 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.